Evidence map›Paper›PMID 34248087›Full record

SynthesisJournal of atherosclerosis and thrombosis2022

Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y

Shqipdona Lahu, Peter Bristot, Senta Gewalt, Alexander Goedel, Daniele Giacoppo, Stefanie Schüpke, Heribert Schunkert, Adnan Kastrati, Nikolaus Sarafoff

Open access · diamondAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of atherosclerosis and thrombosis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Personalized Antithrombotic Therapy After Percutaneous Coronary Intervention: A Systematic Review of Risk-Stratified Approaches.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
    Pooled it
  2. Review
  3. Review
  4. Review of the Ticagrelor Trials Evidence Base.Journal of the American Heart Association · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shqipdona LahuKlinik fuer Herz- und Kreislauferkrankungen, Deutsches Herzzentrum Munich, Technische Universitaet Muenchen.
Peter BristotKlinik fuer Herz- und Kreislauferkrankungen, Deutsches Herzzentrum Munich, Technische Universitaet Muenchen.
Senta GewaltKlinik fuer Herz- und Kreislauferkrankungen, Deutsches Herzzentrum Munich, Technische Universitaet Muenchen.
Alexander GoedelKlinik und Poliklinik fuer Innere Medizin I, Klinikum rechts der Isar, Technische Universitaet Munich.
Daniele GiacoppoKlinik fuer Herz- und Kreislauferkrankungen, Deutsches Herzzentrum Munich, Technische Universitaet Muenchen.
Stefanie SchüpkeKlinik fuer Herz- und Kreislauferkrankungen, Deutsches Herzzentrum Munich, Technische Universitaet Muenchen.
Heribert SchunkertKlinik fuer Herz- und Kreislauferkrankungen, Deutsches Herzzentrum Munich, Technische Universitaet Muenchen.
Adnan KastratiKlinik fuer Herz- und Kreislauferkrankungen, Deutsches Herzzentrum Munich, Technische Universitaet Muenchen.
Nikolaus SarafoffKlinik fuer Herz- und Kreislauferkrankungen, Deutsches Herzzentrum Munich, Technische Universitaet Muenchen.
Digital Research Alliance of CanadaGerman Centre for Cardiovascular Research · DEKlinikum rechts der Isar · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation is an ongoing debate and novel data has emerged. The aim of this meta-analysis was to assess outcomes of short vs. control DAPT duration. In addition, the role of single antiplatelet therapy (SAPT) after DAPT with either aspirin or P2Y

methodsThe authors searched MEDLINE and Cochrane databases and proceedings of international meetings for randomized controlled trials (RCT) comparing ≤ 3 months with ≥ 6 months DAPT after DES implantation. The primary and co-primary outcomes of interest were definite or probable stent thrombosis (ST) and bleeding. In addition, we performed an analysis on studies who continued with either aspirin or P2Y

results9 RCTs comprising 41,864 patients were included and we analyzed a short DAPT duration of median 1.5 months vs. 12.1 months in the control group. The risk for ST was similar with short vs. control DAPT duration (0.5 vs. 0.5%; hazard ratio 1.17[95% CI 0.89-1.54]; p=0.26). Bleeding was significantly reduced with short vs. control DAPT duration (1.9 vs. 3.0%; 0.65[0.54-0.77]; p＜0.0001).ST was not different between short vs. control DAPT duration in the analysis of the 4 RCTs who continued with aspirin after DAPT and the 5 P2Y

conclusionsOur meta-analysis shows that short DAPT ≤ 3 months followed by SAPT reduces bleeding and is not associated with an increase in ST. The results were consistent within the aspirin and P2Y

Indexed as

Drug-Eluting StentsMyocardial InfarctionPercutaneous Coronary InterventionThrombosisAspirinDrug Therapy, CombinationHemorrhageHumansPlatelet Aggregation InhibitorsTime FactorsTreatment OutcomeAspirinPlatelet Aggregation InhibitorsAspirinDrug-eluting stentDual antiplatelet therapyP2Y12 inhibitor

Identifiers

PMID34248087
PMCPMC9252616
OpenAlexW3179075440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.